Skip to main content
OpenTrials
Completed

NCT Number: NCT00655187

Effectiveness of Human Rotavirus Vaccine, Rotarix™ Against Rotavirus Severe Gastroenteritis (RV SGE) in Infants

This study aims to evaluate the effectiveness of Rotarix™ vaccine in the general population in Singapore by monitoring the overall reduction in RV SGE and also by assessing the direct protection offered by the vaccine in hospitalised infants through a case-control study.

Completed

Looking for future studies?

Notify Me

Key information

Age range

Up to 5 year

Sex eligibility

All sexes

Study type

Observational

Primary location

GSK Investigational Site

Singapore, 229899

About this study

This Protocol Posting has been updated following an amendment of the Protocol.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Inclusion criteria

for surveillance subjects

  • A male or female child aged < 60 months at the time of admission (a child becomes ineligible on the day of its fifth birthday).
  • Subject admitted with acute GE as an inpatient to the study site during the study period.
  • Written informed consent obtained from the parent or guardian of the subject. Selection criteria for cases

Cases will be limited to those surveillance subjects:

  • who are born after 1 November 2005 (date of availability of Rotarix™ vaccination in Singapore),
  • who are aged at least 16 weeks at the time of hospital admission.
  • whose stool samples are tested positive for RV. Selection criteria for controls

All controls must satisfy the following criteria at study entry:

  • Admitted for acute disease with non-GE causes in the same hospital as the case , with the closest admission date to the cases.
  • Aged at least 16 weeks at the time of hospital admission.
  • Born within a range of ± 2 weeks from the date of birth of cases. In case there is no suitable match, then the range would be extended to ± 4 weeks.
  • Written informed consent obtained from the subject's parents/guardians.

Exclusion criteria

For enrolment of surveillance subjects

The following criteria should be checked at the time of study entry. If any apply, the subject must not be included in the study:

  • The diagnoses at admission to the study site do not include acute GE.
  • Children for whom stool samples are not available up to 48 hours after admission.
  • The onset of GE is after 48 hours of admission to the hospital (i.e. nosocomial GE).
  • Children with a history of chronic and genetic diseases. For selection of cases

In addition to the exclusion criteria for surveillance subjects, cases will not be selected if the following criterion applies:

  • Subjects who had a previous episode of acute GE less than a week back i.e. recurrent GE episode.
  • Subjects who have been already enrolled in the study.
  • Subjects whose vaccination history could not be ascertained. For selection of controls

The following criteria should be checked at the time of study entry. If any apply, the controls must not be included in the study:

  • Child who has symptoms of GE on the day of interview of his/her parent or guardian or had an episode of GE within 14 days prior to the day of interview.
  • Child who has been already enrolled in the study as case or control.
  • The onset of GE occurs after admission at the hospital.
  • Child whose vaccination history could not be ascertained.

Treatment and study plan

Collection of information

Other

Information regarding demographic characteristics, medical history, previous participation in rotavirus clinical trials and vaccination history will be collected.

Collection of stool samples

Procedure

Stools samples will be collected during hospitalisation for RV testing and genotyping of RV positive samples.

Primary outcomes

  1. To estimate the proportion of acute RV GE hospitalisations in children < 5 years of age.

    Time frame: At least one year

  2. To estimate the effectiveness of two doses of Rotarix™ vaccination in preventing rotavirus severe gastroenteritis (RV SGE) among children born after 1 November 2005 and aged at least 16 weeks.

    Time frame: At least one year

Secondary outcomes

  1. To estimate the effectiveness of two doses of Rotarix™ vaccination in preventing hospitalisation for acute RV GE among children born after 1 November 2005 and aged at least 16 weeks.

    Time frame: At least one year

  2. To determine the distributions of acute RV GE associated hospital admissions according to subject's age, gender and by month of year.

    Time frame: At least one year

  3. To estimate the prevalence of RV genotypes in acute RV GE associated hospital admission.

    Time frame: At least one year

  4. To review the trend of acute RV GE and acute GE admissions over the entire study period.

    Time frame: At least one year

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

Case-control Study to Evaluate the Vaccine Effectiveness of Rotarix™ Against Rotavirus Severe Gastroenteritis (RV SGE) Among Hospitalised Children < 5 Years of Age in KK Hospital, Singapore

Important dates

Study start
2008
Primary completion
2010
Study completion
2010
First posted
Apr 9, 2008
Registry last updated
May 30, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.